Whether complete correction of anemia in patients with stage 3 or 4 kidney disease improves cardiovascular outcome is not established. In this study, patients with an estimated glomerular filtration rate of 15 to 35 ml per minute and mild-to-moderate anemia were randomly assigned to receive treatment with erythropoietin to increase their hemoglobin levels to either normal or subnormal. The results suggest that early, complete correction of anemia does not reduce cardiovascular events.

Recombinant human erythropoietin is indicated for the correction of anemia in chronic kidney disease, but the optimal target level of hemoglobin is unknown. In this open-label study, epoetin alfa was given to achieve a high (13.5 g per deciliter) or a low (11.3 g per deciliter) target hemoglobin level. The higher target level was associated with an increased risk of adverse events without an improvement in quality of life.

The authors investigated whether tolvaptan, an orally active vasopressin V₂-receptor antagonist that promotes electrolyte-free water loss, might improve hyponatremia. Serum sodium concentrations in patients with euvolemic or hypervolemic hyponatremia and mild or marked hyponatremia improved with therapy at day 4 and day 30. Tolvaptan holds promise for treating patients with hyponatremic states.

In a pilot trial, 52 patients with coronary disease and restenosis of a previously placed intracoronary stent underwent angioplasty with either a paclitaxel-coated balloon or an uncoated balloon. Late luminal loss and the incidence of restenosis at 6 months were significantly reduced with the paclitaxel-coated balloon, as was the rate of target-vessel revascularization at 1 year. The results of this small proof-of-concept study will require confirmation in larger clinical trials.